

<p style="text-align: center;">REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL</p> <p>Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).</p>	<i>Application Number</i>	10/572,502
	<i>Filing Date</i>	March 17, 2006
	<i>First Named Inventor</i>	Nitin Bhalachandra Dharmadhikari
	<i>Confirmation Number</i>	4377
	<i>Group Art Unit</i>	1618
	<i>Examiner Name</i>	Micah Young
	<i>Attorney Docket Number</i>	2867.003US1
	<i>Customer No.</i>	21186

This is a Request for Continued Examination (RCE) under 37 C.F.R § 1.114 of the above-identified application entitled

ORAL DRUG DELIVERY SYSTEM

1. Submission required under 37 C.F.R. § 1.114:

☒ Amendment Under 37 C.F.R § 1.116 (20 pages) is enclosed.


☒ Replacement Drawings (3 pgs)

2. Fees

☒ Authorization to charge deposit account 19-0743 in the amount of \$810.00 to pay the RCE filing fee required under 37 C.F.R. § 1.17(e).

☒ **The Commissioner is hereby authorized to charge any additional fees or credit overpayment to Deposit Account No. 19-0743.**

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.

By: 
Louis M. Leichter, Ph.D., J.D.
Reg. No. 34,657

CERTIFICATE UNDER 37 C.F.R 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 29 day of September, 2010.

John D. Gustav-Wrathall

Name


Signature